Idiopathic pulmonary fibrosis (IPF) is a severe and often fatal disease with a median survival
of 2–4 years after diagnosis. Since the publication of the German IPF guideline in 2013 new …

Idiopathic pulmonary fibrosis (IPF) is a fatal progressive lung disease occurring in adults. In
the last decade, the results of a number of clinical trials based on the updated disease …

Background: Clinical practice guidelines for the treatment of idiopathic pulmonary fibrosis
(IPF) currently recommend pirfenidone and nintedanib. However, there is a lack of evidence …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …

A comment on this article appears in"[Reply]." Pneumologie. 2013 Jun; 67 (6): 356. A
comment on this article appears in"[S2K guideline on diagnosis and treatment of idiopathic …

Background Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor
prognosis. Our objective is to assess the comparative effectiveness of 22 approved or …

Background Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with
high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies …

Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …

Recently updated guidelines have provided revised recommendations, based on the
GRADE criteria, for the diagnosis and pharmacological and non-pharmacological …